XXII: Rega Tumbas Perusahaan 22nd Century Group

22nd Century Group (XXII) is developing low-nicotine tobacco production, monetizing biotech patents through seed licensing. The genetics team is creating innovative varieties to improve human health. This price chart reflects that the Enterprise Value is -4.24. The company's monopoly position is secured by FDA approval and unique bioengineering developments, which create a powerful moat against competitors.

XXII (xxiicentury.com) riwayat Nilai Total Perusahaan saka 23.11.2025 nganti 28.10.2026

Rincian analitis perusahaan 22nd Century Group

- rega lan prakiraan konsensus rega:

Kurs saham 22nd Century Group Inc.|XXII - Prakiraan konsensus analis

- data kapitalisasi pasar:

Kapitalisasi pasar 22nd Century Group|XXII - Nilai Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Saham 22nd Century Group|XXII - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku xxiicentury.com|XXII - Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal 22nd Century Group|XXII - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal 22nd Century Group Inc.|XXII - Gunggung utang perusahaan|Utang marang nilai buku 22nd Century Group|XXII - Utang jangka dawa perusahaan|Utang jangka cendhak 22nd Century Group

Pambiji fundamental perusahaan:22nd Century Group (XXII)

Investors utilize this metric as an objective business acquisition cost that accounts for the combination of equity and net debt. The current value of -4.24, represented via the market valuation of assets excluding liquidity, reflects the real price of 22nd Century Group (XXII), which remains stable due to the absence of external geopolitical risks and the company's exclusive focus on the US domestic market.

Pesaing langsung